Posted by Michael Wonder on 24 Jun 2021
Biogen expects slow Alzheimer’s drug uptake, may reset price
24 June 2021 - Company faces uproar over $56,000 a year price tag for Aduhelm.
The disclosure in a company statement Wednesday is a signal the drugmaker wants to tamp down the outcry over the treatment’s potential costs to the U.S. health care system.
The company said it set the price based on the impact of the treatment and assumptions about how many people would take it.
